|
|
|
| The effect of tranexamic acid administration on the endothelial glycocalyx degradation in vascular endothelial cell at different time |
| HU Lei |
| Department of Emergency, Jinhua Central Hospital, Jinhua, 321000 |
|
| Cite this article: |
|
HU Lei. The effect of tranexamic acid administration on the endothelial glycocalyx degradation in vascular endothelial cell at different time[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2018, 48(10): 712-717.
|
|
|
|
Abstract Objective: To investigate the effect of tranexamic acid (TXA) on glycocalyx damage in human umbilical vein endothelial cells (HUVECs) following H2O2 injury. Methods: In vitro HUVECs were exposed to H2O2 to stimulate post-shock reperfusion. TXA was added during H2O2 incubation (30 minutes and 60 minutes) and at 1 hour and 2 hours before the termination of H2O2 exposure. The cellular morphology was observed using a fluorescence microscope after Hoechst 33258 staining. Endothelial cell injury was indexed by caspase-3 as well as ICAM expression and TNF-α release. Glycocalyx degradation was indexed by syndecan and HLA release. Activation of endothelial sheddases was indexed by MMP-9 content in HUVECs. Transwell assay was performed to explore the invasive property of HUVECs. Results: Exposure of HUVECs to H2O2 results in glycocalyx disruption demonstrated by promoted apoptosis and increased levels of caspase-3, syndecan, HLA, TNF-α, ICAM and MMP-9. TXA administration within 60 minutes of H2O2 treatment results in preservation of the glycocalyx. TXA administration after 60 minutes is no glycocalyx protective effect on HUVECs. Conclusion: TXA is exerted as an endothelial protector via inhibition of glycocalyx degradation. This effect is not apparent when TXA was administered after 60 minutes of H2O2 exposure.
|
|
Received: 09 January 2018
|
| |
|
|
|
[1] JIANG X Z, GONG H, LUO K H, et al. Large-scale molecular dynamics simulation of coupled dynamics of flow and glycocalyx: towards understanding atomic events on an endothelial cell surface[J]. J R Soc Interface, 2017, 14(137): 20170780.
[2] GONZALEZ RODRIGUEZ E, OSTROWSKI S R, CARDENAS J C, et al. Syndecan-1: A quantitative marker for the endotheliopathy of trauma[J]. J Am Coll Surg, 2017, 225(3): 419-427.
[3] FLAHERTY K, BATH P M, DINEEN R, et al. Statistical analysis plan for the ‘Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage’ (TICH-2) trial[J]. Trials, 2017, 18(1): 607.
[4] BOETTNER F, RUECKL K. Benefits of tranexamic acid not debatable but leave tourniquet use to surgeon’s discretion: commentary on an article by ZeYu Huang, MD, PhD, et al.: “Intravenous and topical tranexamic acid alone are superior to tourniquet use for primary total knee arthroplasty. A prospective, randomized controlled trial”[J]. J Bone Joint Surg Am, 2017, 99(24): e135.
[5] LI T, LIU X, ZHAO Z, et al. Sulodexide recovers endothelial function through reconstructing glycocalyx in the balloon-injury rat carotid artery model[J]. Oncotarget, 2017, 8(53): 91350-91361.
[6] TARGOSZ-KORECKA M, JAGLARZ M, MALEK-ZIETEK K E, et al. AFM-based detection of glycocalyx degradation and endothelial stiffening in the db/db mouse model of diabetes[J]. Sci Rep, 2017, 7(1): 15951.
[7] YAN J, WANG J, HUANG H, et al. Fibroblast growth factor 21 delayed endothelial replicative senescence and protected cells from H2O2-induced premature senescence through SIRT1[J]. Am J Transl Res, 2017, 9(10): 4492-4501.
[8] LIOU C J, HUANG W C. Casticin inhibits interleukin-1β-induced ICAM-1 and MUC5AC expression by blocking NF-κB, PI3K-Akt, and MAPK signaling in human lung epithelial cells[J]. Oncotarget, 2017, 8(60): 101175-101188.
[9] GALORE-HASKE G, BARUCH E N, BERG A L, et al. Histopathological expression analysis of intercellular adhesion molecule 1 (ICAM-1) along development and progression of human melanoma[J]. Oncotarget, 2017, 8(59): 99580-99586.
[10] KURNIK N M, PFLIBSEN L R, DO A, et al. Craniosynostosis surgery and the impact of tranexamic acid dosing[J]. J Craniofac Surg, 2018, 29(1): 96-98.
[11] BUTWICK A J, DENEUX-THARAUX C, SENTILHES L. Tranexamic acid for the management of obstetric hemor-rhage[J]. Obstet Gynecol, 2017, 130(6): 1386.
[12] DUEBEL L N, MARTIN J V, LIBERATI D M. Early tranexamic acid administration ameliorates the endotheliopathy of trauma and shock in an in vitro model[J]. J Trauma Acute Care Surg, 2017, 82(6): 1080-1086.
[13] GIEGER T L, NETTIFEE-OSBORNE J, HALLMAN B,
et al. The impact of carboplatin and toceranib phosphate on serum vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9) levels and survival in canine os-teosarcoma[J]. Can J Vet Res, 2017, 81(3): 199-205.
[14] COOPER S, MCDONALD K, BURKAT D, et al. Stenosis Hemodynamics disrupt the endothelial cell glycocalyx by MMP activity creating a proinflammatory environment[J]. Ann Biomed Eng, 2017, 45(9): 2234-2243.
[15] ALONI P D, NAYAK A R, CHAURASIA S R, et al. Effect of Fagonia arabica on thrombin induced release of t-PA and complex of PAI-1 tPA in cultured HUVE cells[J]. J Tradit Complement Med, 2015, 6(3): 219-223.
[16] ALTAF M, STOECKLI-EVANS H. A copper(II) paddle-wheel structure of tranexamic acid: di-chloro-tetra-kis-[μ-4-(ammonio-meth-yl)cyclo-hexane-1-carboxyl-ato-O,O’]dicopper(II) dichloride hexa-hydrate[J]. Acta Crystallogr E Crystallogr Commun, 2017, 73(Pt 10): 1421-1425.
[17] DIEBEL L N, MARTIN J V, LIBERATI D M. Early tranexamic acid administration ameliorates the endotheliopathy of trauma and shock in an in vitro model[J]. J Trauma Acute Care Surg, 2017, 82(6): 1080-1086. |
|
|
|
